# iCorNet Laboratory

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/icornet-laboratory

- Industry: Medical Devices & Equipment
- Headquarters: Nagoya-shi, Japan
- Website: www.icornet.jp/
- Total disclosed funding: $3.3M
- Latest round: Series B (Mar 29, 2021)
- Investors on record: 6

## About

Based in Japan, iCorNet Laboratory specializes in developing innovative solutions for treating dilated cardiomyopathy (DCM), focusing on enhancing patient quality of life through advanced medical devices.Established in 2016 and headquartered in Nagoya-shi, Japan, iCorNet Laboratory develops medical devices targeting dilated cardiomyopathy (DCM). The company has completed 2 deals, with the latest funding round being a Series B that raised JPY 210 million on March 29, 2021, from investors including AMCO INC., DVx, Inc., Kondo-Labo, Nagoya Small and Medium Business Investment & Consultation, and Shizuoka Capital. The total amount raised to date is JPY 210 million, with a current valuation of JPY 1,503.529 million.iCorNet Laboratory focuses on researching and developing innovative solutions for dilated cardiomyopathy (DCM). Their flagship product, the "Cardiac Support Net," aims to alleviate symptoms and slow DCM progression by providing structural support to the heart, thus lessening the burden on the failing organ. The device is designed with advanced materials for a tailored fit, targeting approximately 20,000 patients with DCM in Japan, with plans for expansion into North America and Europe.iCorNet Laboratory's revenue model is anticipated to derive from direct-to-consumer sales and partnerships with healthcare providers. The Cardiac Support Net is recommended by healthcare professionals, with transactions structured around reimbursements and direct purchases. The company is finalizing clinical trials to secure regulatory approvals, facilitating commercialization and revenue generation through product sales and collaborations with heart disease treatment institutions.iCorNet Laboratory plans to leverage the JPY 210 million raised in the Series B funding round to further develop their product line and expand into new markets. The focus includes launching new products for treating heart conditions and targeting North America and Europe for market expansion by the end of 2023. The recent funding will support marketing efforts and clinical validation to enhance product visibility and accessibility.

## Funding rounds

- Series B, Mar 29, 2021, $1.9M — DVx, Inc, Shizuoka Capital, Nagoya Small and Medium Business Investment & Consultation, AMCO INC., Kondo-Labo
- Series A, Feb 9, 2018, $1.4M — Nissay Capital

## Investors

- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series A
- DVx, Inc — Series B
- Shizuoka Capital (https://capitalatlas.ai/funds/shizuoka-capital) — Series B
- Nagoya Small and Medium Business Investment & Consultation (https://capitalatlas.ai/funds/nagoya-small-and-medium-business-investment-consultation) — Series B
- AMCO INC. — Series B
- Kondo-Labo — Series B